文献速递产科母胎医学

产前肾脏超声异常与致病性拷贝数变异在中国大样本中的关联

Association of prenatal renal ultrasound abnormalities with pathogenic copy number variants in a large Chinese cohort.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

该回顾性研究分析了2013年至2019年间877例产前超声发现肾脏异常并接受染色体微阵列分析(CMA)的胎儿,评估致病或可能致病拷贝数变异(P/LP CNV)与不同肾脏异常类型的关联。结果显示不同肾脏异常类型的P/LP CNV检出率差异显著(3.03%-39.58%),其中高回声肾检出率最高(39.58%),17q12缺失是最常见致病CNV(占阳性30.14%)。研究建议高回声肾无论孤立与否应行产前CMA,而肾盂扩张建议产后检测。

要点

  • 高回声肾的P/LP CNV检出率最高(39.58%),无论孤立与否均建议产前CMA检测。
  • 肾盂扩张最常见(34.32%),但P/LP CNV检出率仅3.65%,建议产后而非产前CMA检测。
  • 17q12缺失是最常见致病CNV,占所有阳性CMA的30.14%,肾脏表型广泛。

核心结论

  • 不同产前肾脏超声异常类型的P/LP CNV检出率差异显著(3.03%-39.58%),CMA结果可辅助决定是否行产前遗传学检测。
  • 高回声肾无论孤立与否应行产前CMA,而肾盂扩张建议产后而非产前检测。

研究设计与样本

  • 回顾性研究,纳入2013年1月至2019年11月在广西壮族自治区妇幼保健院常规筛查的14-36周胎儿。
  • 分析877例肾脏超声异常且接受CMA检测(绒毛膜绒毛取样、羊膜腔穿刺或脐带血穿刺)的胎儿数据。
  • 根据肾脏异常类型及是否孤立评估CMA结果。

主要发现

  • 肾盂扩张最常见(34.32%,301/877),P/LP CNV检出率3.65%(11/301),孤立型2.37%(4/169),非孤立型5.30%(7/132)。
  • 高回声肾占5.47%(48/877),P/LP CNV检出率39.58%(19/48),孤立型44.44%(16/36),非孤立型25.00%(3/12),为各类型中最高。
  • 肾缺如占9.92%(87/877),CMA诊断率12.64%(11/87),孤立型11.54%(9/78),非孤立型22.22%(2/9),单侧11.39%(9/79),双侧25.00%(2/8);多囊性发育不良肾(n=110)、肾囊肿(n=34)、肾发育不良(n=27)、交叉融合异位肾(n=31)、肾积水(n=98)、重复肾(n=42)和异位肾(n=99)的诊断率分别为11.82%、11.76%、7.41%、6.45%、6.12%、4.76%和3.03%。
  • CMA阴性且孤立性肾盂扩张或异位肾的胎儿出生时存活且健康率显著高于其他CMA阴性肾脏异常组,而孤立性肾缺如、多囊性发育不良肾或重度肾积水的胎儿该率显著降低。
  • 最常见致病CNV为17q12缺失,占所有阳性CMA的30.14%(22/73),在肾脏异常胎儿中占2.51%(22/877),表型广泛;其他反复区域P/LP CNV包括22q11.2、Xp21.1、Xp22.3、2q13、16p11.2和1q21,合计占2.17%(19/877)。

关键数值与推荐

  • 高回声肾:P/LP CNV检出率39.58%(19/48),孤立型44.44%(16/36),非孤立型25.00%(3/12),为最高诊断率。
  • 肾盂扩张:P/LP CNV检出率3.65%(11/301),孤立型2.37%(4/169),非孤立型5.30%(7/132)。
  • 肾缺如:CMA诊断率12.64%(11/87),孤立型11.54%(9/78),非孤立型22.22%(2/9),单侧11.39%(9/79),双侧25.00%(2/8)。
  • 17q12缺失占阳性CMA的30.14%(22/73),在肾脏异常胎儿中占2.51%(22/877)。

临床怎么用

  • 产前超声发现高回声肾时,无论是否孤立,应行CMA检测。
  • 产前超声发现肾盂扩张时,建议产后而非产前行CMA检测。
  • CMA结果可辅助咨询不同肾脏异常类型的遗传学病因及预后。

局限性

  • 回顾性研究设计。
  • 64%的孤立性肾脏异常病例接受脐带血穿刺而非绒毛膜绒毛取样,诊断孕周较晚(平均24.9±4.8周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the clinical utility of prenatal chromosomal microarray analysis (CMA) in fetuses with abnormal renal sonographic findings, and to evaluate the association of pathogenic or likely pathogenic copy number variants (P/LP CNVs) with different types of renal abnormality. METHODS: This was a retrospective study of fetuses at 14-36 weeks screened routinely for renal and other structural abnormalities at the Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region. We retrieved and analyzed data from fetuses with abnormal renal sonographic findings, examined between January 2013 and November 2019, which underwent CMA analysis using tissue obtained from chorionic villus sampling (CVS), amniocentesis or cordocentesis. We evaluated the CMA findings according to type of renal ultrasound anomaly and according to whether renal anomalies were isolated or non-isolated. RESULTS: Ten types of renal anomaly were reported on prenatal ultrasound screening, at a mean ± SD gestational age of 24.9 ± 4.8 weeks. The anomalies were diagnosed relatively late in this series, as 64% of cases with an isolated renal anomaly underwent cordocentesis rather than CVS. Fetal pyelectasis was the most common renal ultrasound finding, affecting around one-third (34.32%, 301/877) of fetuses with a renal anomaly, but only 3.65% (n = 11) of these harbored a P/LP CNV (comprising: isolated cases, 2.37% (4/169); non-isolated cases, 5.30% (7/132)). Hyperechogenic kidney was found in 5.47% (n = 48) of fetuses with a renal anomaly, of which 39.58% (n = 19) had a P/LP CNV finding (comprising: isolated cases, 44.44% (16/36); non-isolated cases, 25.00% (3/12)), the highest diagnostic yield among the different types of renal anomaly. Renal agenesis, which accounted for 9.92% (n = 87) of all abnormal renal cases, had a CMA diagnostic yield of 12.64% (n = 11) (comprising: isolated cases, 11.54% (9/78); non-isolated cases, 22.22% (2/9); unilateral cases, 11.39% (9/79); bilateral cases, 25.00% (2/8)), while multicystic dysplastic kidney (n = 110), renal cyst (n = 34), renal dysplasia (n = 27), crossed fused renal ectopia (n = 31), hydronephrosis (n = 98), renal duplication (n = 42) and ectopic kidney (n = 99) had overall diagnostic rates of 11.82%, 11.76%, 7.41%, 6.45%, 6.12%, 4.76% and 3.03%, respectively. Compared with the combined group of CMA-negative fetuses with any other type of renal anomaly, the rate of infant being alive and well at birth was significantly higher in CMA-negative fetuses with isolated fetal pyelectasis or ectopic kidney, whereas the rate was significantly lower in fetuses with isolated renal agenesis, multicystic dysplastic kidney or severe hydronephrosis. The most common pathogenic CNV was 17q12 deletion, which accounted for 30.14% (22/73) of all positive CMA findings, with a rate of 2.51% (22/877) among fetuses with an abnormal renal finding. Fetuses with 17q12 deletion exhibited a wide range of renal phenotypes. Other P/LP CNVs in the recurrent region that were associated with prenatal renal ultrasound abnormalities included 22q11.2, Xp21.1, Xp22.3, 2q13, 16p11.2 and 1q21, which, collectively, accounted for 2.17% (19/877) of the fetuses with prenatal renal anomalies. CONCLUSIONS: In this retrospective review of CMA findings in a large cohort of fetuses with different types of renal ultrasound abnormality, the P/LP CNV detection rate varied significantly (3.03-39.58%) among the different types of kidney anomaly. Our data may help in the decision regarding whether to perform prenatal genetic testing in fetuses with renal ultrasound findings. Specifically, prenatal CMA testing should be performed in cases of hyperechogenic kidney, regardless of whether or not the anomaly is isolated, while it should be performed postnatally rather than prenatally in cases of fetal pyelectasis. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Su J, Qin Z, Fu H, et al. Association of prenatal renal ultrasound abnormalities with pathogenic copy number variants in a large Chinese cohort. Ultrasound Obstet Gynecol. 2022. PMID: 34090309. doi:10.1002/uog.23702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。